Colonoscopic Findings in Patients with a Positive Fecal Occult Blood Test: A Descriptive Study

Authors

  • Edison Javier Moreira Granda Hospital General de Agudos Dr. Ignacio Pirovano. https://orcid.org/0000-0003-4969-1175
  • Santiago Regnasco Hospital General de Agudos Dr. Ignacio Pirovano. https://orcid.org/0009-0003-6478-9055
  • Josefina Romero Hospital General de Agudos Dr. Ignacio Pirovano. https://orcid.org/0009-0005-2188-6634
  • Itatí Guerríeri Hospital General de Agudos Dr. Ignacio Pirovano. https://orcid.org/0009-0008-0840-4380
  • Susana Misino Hospital General de Agudos Dr. Ignacio Pirovano.
  • Diego Gariglio Hospital General de Agudos Dr. Ignacio Pirovano.
  • Bárbara Chiussi Hospital General de Agudos Dr. Ignacio Pirovano.
  • Hernán Bracone Hospital General de Agudos Dr. Ignacio Pirovano.
  • Emilia Saá Hospital General de Agudos Dr. Ignacio Pirovano. https://orcid.org/0009-0005-4513-9246

DOI:

https://doi.org/10.52787/agl.v54i4.443

Keywords:

Colorectal neoplasms, fecal occult blood test, colonoscopy, colorectal cancer screening

Abstract

Introduction. Colorectal cancer is one of the most frequent neoplasms and a serious public health concern worldwide. In 2020, in Argentina, 15,605 new cases of colorectal cancer were registered and, in 2022, 7,217 deaths representing 12% of all deaths from malignant tumors. The National Program for the Prevention and Early Detection of Colorectal Cancer recommends that people between 50 and 75 years of age with no personal or family history of colorectal cancer, no history of inflammatory bowel disease, no suggestive symptoms, and no known risk factors should undergo biennial immunological fecal occult blood test. For at-risk groups, specific evaluations are performed based on their specific needs. A positive result of the immunologic fecal occult blood test requires a colonoscopy, the most sensitive test for early detection.

Aim. To assess the rate of TSOMF-I with a positive result. To describe the percentage of patients who undergo VCC after a positive TSOMF-I result. To assess the adenoma detection rate and prevalence of CRC in patients with TSOMF-I positive.

Materials and methods. A retrospective analysis was performed, in which data were collected from individuals between 50 and 75 years of age with positive immunologic fecal occult blood test and colonoscopies performed at Hospital Pirovano, Ciudad Autónoma de Buenos Aires, from January 1, 2020 to January 1, 2024.

Results. A total of 717 patients were evaluated. A positive result on immunologic fecal occult blood test was observed in 21.6% (n=155) of the cohort, but only 42.6% (n=66) underwent colonoscopy. Findings were identified in 80% of cases, predominantly polyps (36.4%), internal hemorrhoids (34.8%), diverticulosis (18.1%) and angiectasis (4.5%). The prevalence of colorectal cancer was 3%, with an adenoma detection rate of 33.3%. Conclusion. This study showed a high prevalence of colorectal lesions, including adenomas and colorectal cancer, with figures that resemble those published by other international studies. The results obtained reflect the efficacy of immunological fecal occult blood test screening to identify relevant colorectal lesions. A key finding was that less than half of the patients with positive immunological fecal occult blood test underwent subsequent colonoscopy, which indicates the existence of important barriers to access to this study in our setting and reinforces the need to implement strategies to increase it. These findings are crucial to optimizing colorectal cancer screening programs in Argentina, adapting them to the needs of the local population, and improving public health outcomes.

References

-1. Yonamine K, Kirschbaum A. Recomendaciones para el tamizaje organizado de Cáncer Colorrectal en población de riesgo promedio en Argentina - 1a ed. - Ciudad Autónoma de Buenos Aires: Instituto Nacional del Cáncer; 2022.

-2. Sguiglia S. Nuevas recomendaciones para el tamizaje de cáncer colorrectal en Argentina. Evid actual pract ambul [Internet]. 2 de junio de 2023 [citado 21 de febrero de 2024];26(2):e007067. Disponible en: https://evidencia.org.ar/index.php/Evidencia/article/view/7067

-3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May 4;71.

-4. González N, et al. Hallazgos colonoscópicos en una población de pacientes con test de sangre oculta en heces positivos. Arch Med Int. 2011;33(2):21-23. ISSN 0250-3816.

-5. Ribbing Wilén H, Blom J, Höijer J, Hultcrantz R. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels. J Gastroenterol Hepatol. 2018. DOI:10.1111/jgh.14373

-6. Hunt JS, Cock C, Symonds EL. A True Positive and a False Negative? The Dilemma of Negative Colonoscopy After a Positive Fecal Occult Blood Test. Dig Dis Sci. 2022;67:1843-1849. DOI:10.1007/s10620-021-06986-4

-7. Zhong GC, Sun WP, Wan L, Hu JJ, Hao FB. Eficacia y rentabilidad de la prueba inmunoquímica fecal versus colonoscopia en la detección del cáncer colorrectal: una revisión sistemática y un metanálisis. Endoscopia gastrointestinal. 2019. DOI: https://doi.org/10.1016/j.gie.2019.11.035

-8. Agustín Kirschbaum; Karina Gisele Yonamine- Indicadores de calidad para videocolonoscopía en tamizaje de cáncer colorrectal. Recomendaciones basadas en evidencia /. 1a ed. - Ciudad Autónoma de Buenos Aires: Instituto Nacional del Cáncer, 2019.

-9. Fernandez JL, Gallegos M, Brochero A. Screening for colorectal cancer with an immunological fecal occult blood test. Acta Gastroenterol Latinoam. 1999 [citado 11 Abril 2024];29(2):73-78. Disponible en: https://pubmed.ncbi.nlm.nih.gov/10491719/

-10. Vietto V, Belardinelli S, Rubinstein F, Terrasa S. Cascada diagnóstica consecutiva al rastreo de cáncer colorrectal con sangre oculta en materia fecal: estudio de cohorte retrospectiva. Arch Med Fam Gen. 2017 [citado 15 Abril 2024];14(1):6-11. Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-907419

-11. Ruiz EF. Indicadores de desempeño de un programa de rastreo de cáncer colorrectal en la provincia del Neuquén, Argentina, 2015-2019. Rev Argent Salud Pública. 2022;14. Disponible en: https://rasp.msal.gov.ar/index.php/rasp/article/view/757/770

-12. Galvarini, M. (2020). Estudio prospectivo acerca de la precisión diagnóstica del test inmunológico de sangre oculta en materia fecal en una única ronda para la realización de pesquisa del cáncer colorrectal en pacientes de riesgo promedio en la Argentina. Revista Argentina de Coloproctología, 31(04). https://www.revistasacp.com/index.php/revista/article/view/64

-13. Fenocchi E, Martinez L, Tolve J, Montano D, Rondan M, Parra-Blanco A, et al. Screening for colorectal cancer in Uruguay with an immunochemical faecal occult blood test. Eur J Cancer Prev. 2006 [citado 16 Mayo 2024];15(5):384-390. Disponible en: https://pubmed.ncbi.nlm.nih.gov/16912566/

-14. Altemburg F, Biondo-Simoes M, Von Bahten L. A pesquisa de sangue oculto nas fezes associada a um questionário de sinais e sintomas na prevenção do câncer colo retal. Rev Brasileira de Coloproctologia. 2009 [citado 08 Junio 2024];29(1):57-64. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttex-t&pid=S0101-98802009000100008

Published

2024-12-30

How to Cite

Moreira Granda, E. J., Regnasco, S., Romero, J., Guerríeri, I., Misino, S., Gariglio, D., Chiussi, B., Bracone, H., & Saá, E. (2024). Colonoscopic Findings in Patients with a Positive Fecal Occult Blood Test: A Descriptive Study. Acta Gastroenterológica Latinoamericana, 54(4), 318–326. https://doi.org/10.52787/agl.v54i4.443